Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CSPC Pharmaceutical Group ( (HK:1093) ) has provided an update.
CSPC Pharmaceutical Group announced that its Shenzhen-listed subsidiary, CSPC Innovation Pharmaceutical, has published its 2025 annual report prepared under China Accounting Standards, revealing a year of revenue growth but a sharp swing to loss. The company cautioned investors that these figures reflect CSPC Innovation’s consolidated performance rather than that of the parent group, and highlighted a significant decline in net profit and net assets despite improved operating cash flow, underscoring financial pressure at the innovation unit that stakeholders should factor into their assessment of the group’s overall risk profile.
CSPC Innovation reported 2025 operating revenue of RMB 2.16 billion, up 8.93% year on year, but posted a net loss attributable to shareholders of RMB 241 million versus profits in 2024 and 2023, with earnings per share turning negative and return on net assets falling to -6.96%. While total assets edged up 4.22% to RMB 6.28 billion and operating cash outflows narrowed markedly, net assets attributable to shareholders dropped 28.50%, reflecting sustained margin and profitability pressures at the subsidiary that may weigh on its capacity to fund innovation and could influence investor sentiment toward CSPC’s growth strategy.
The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.70 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong–incorporated pharmaceutical company with a focus on innovative drug development and manufacturing, operating through subsidiaries such as CSPC Innovation Pharmaceutical Co., Ltd., which is listed on the ChiNext Market of the Shenzhen Stock Exchange. The group targets the Chinese healthcare market with a portfolio spanning research-driven and specialty medicines.
YTD Price Performance: 1.90%
Average Trading Volume: 121,065,610
Technical Sentiment Signal: Buy
Current Market Cap: HK$98.81B
For an in-depth examination of 1093 stock, go to TipRanks’ Overview page.